Drugs / Montamide
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07328087 Background | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Montamide | “mixed 1:1 with Montamide (2 mg/mL) to a final volume of 1 mL for subcutaneous injection” NCT07328087 ↗ |
| Route | Subcutaneous | “Montamide (2 mg/mL) to a final volume of 1 mL for subcutaneous injection” NCT07328087 ↗ |